亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Engineered Respiratory Syncytial Viruses with Control of Cell-to-Cell Virus Transmission for Enhanced Safety of Live Virus Vaccines

總結
OSU researchers have developed a method to control the rate of cell-to-celltransmission of human RSV, making it possible to tailor vaccines to thestrength each person needs for maximum protection without side effects.  The method also allows for the creation of anon-functional RSV which could be used for immunocompromised patients whorequire more stringent safety conditions. The vaccine created from this method would be easy to produce sincethere is no need to for weakened RSV.
技術優勢
Virus cell to cell transmission can be blocked entirely or fine-tuned to different levels Improved vaccine safety Higher antigen production, recognition, and efficacy Easier production than attenuated viruses Controlled spread of virus without negative side effects
技術應用
Prevention of human RSV outbreaks
詳細技術說明
None
*Abstract
None
*Background
Respiratory Syncytial Virus (RSV) is the largest viral cause ofpediatric bronchiolitis worldwide, a respiratory disease that results in over100,000 deaths per year.  RSV can alsocause adult lung diseases such as pneumonia and poses a serious risk for theelderly and the immunocompromised.  Unfortunately,a vaccine for RSV is not currently available. Although, live-attenuated (weakened) RSV virus offers the most promisefor a future vaccine, previous and current efforts have failed to produce avaccine that is both effective and safe to use without the risk of severe sideeffects.
*Stage of Development
Proof of concept stage.
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備